Free Trial
NASDAQ:TARA

Protara Therapeutics Q3 2024 Earnings Report

Protara Therapeutics logo
$3.34 -0.03 (-0.89%)
Closing price 05/7/2025 03:59 PM Eastern
Extended Trading
$3.29 -0.05 (-1.62%)
As of 07:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protara Therapeutics EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.50
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Protara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Protara Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Protara Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025

Protara Therapeutics Earnings Headlines

Am I wrong for thinking this about you?
The media says Trump supporters are giving up. But I know the truth: you’re the kind of American who doesn’t flinch when the going gets tough. And now there’s a legal, tax-free IRS strategy created under President Trump that could protect your retirement savings from Bidenflation and beyond.
See More Protara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protara Therapeutics and other key companies, straight to your email.

About Protara Therapeutics

Protara Therapeutics (NASDAQ:TARA), a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

View Protara Therapeutics Profile

More Earnings Resources from MarketBeat